• Explore /
  • Poster
  • / Phase 2 trial of zolbetuximab in combination with mFOLFOX6 and nivolumab in patients with advanced or metastatic claudin 18.2-positive, HER2-negative gastric or gastroesophageal junction adenocarcinomas.

Phase 2 trial of zolbetuximab in combination with mFOLFOX6 and nivolumab in patients with advanced or metastatic claudin 18.2-positive, HER2-negative gastric or gastroesophageal junction adenocarcinomas.

Abstract Poster

Authors

Kohei Shitara

Kohei Shitara

Department of gastroenterology and gastrointestinal oncology, National Cancer Center Hospital East, Kashiwa, Japan

Kohei Shitara , Kensei Yamaguchi , Hirokazu Shoji , Maria Matsangou , Pranob P. Bhattacharya , Jung Wook Park , Samuel J Klempner

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Track

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Sub Track

Esophageal or Gastric Cancer - Advanced/Metastatic Disease

Clinical Trial Registration Number

NCT03505320

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr TPS4173)

DOI

10.1200/JCO.2023.41.16_suppl.TPS4173

Abstract #

TPS4173

Poster Bd #

493a

Abstract Disclosures

Similar Posters

First Author: Manish A. Shah

First Author: Diarmuid Martin Moran

First Author: Simon Pernot

First Author: Manish A. Shah